OrthoQB

Evidence library

The trials, meta-analyses and guidelines that shape orthopaedic diagnosis and management, each summarised in one screen: what it asked, what it found, and how it changed practice. Every citation is checked against PubMed.

AllDiagnosisManagementPrognosisPrevention
All topicsShoulderElbowWristHandPeripheral nerveHip (young adult & sports)Hip arthroplastyKnee soft tissue & sportsKnee arthroplastyFoot & ankleSpineUpper limb traumaPelvis & acetabulumLower limb traumaMajor trauma & polytraumaFracture clinic & non-operative carePost-op care & complicationsOperative technique & equipmentInfectionPaediatricsTumoursRheumatology & metabolic boneBasic scienceResearch, statistics & guidelines
ARCHThe New England journal of medicine 2017
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Romosozumab-then-alendronate significantly reduced new vertebral, clinical and hip fractures compared with alendronate alone.
Randomised trialManagementRheumatology & metabolic bone
FRAMEThe New England journal of medicine 2016
Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
Romosozumab significantly reduced new vertebral fractures at 12 months, with the benefit maintained after switching to denosumab; non-vertebral fracture reduction was not significant.
Randomised trialManagementRheumatology & metabolic bone
FREEDOMThe New England journal of medicine 2009
Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
Denosumab significantly reduced new vertebral fractures (by about two thirds), with significant reductions in hip and non-vertebral fractures.
Randomised trialManagementRheumatology & metabolic bone
HORIZON-RFTThe New England journal of medicine 2007
Zoledronic acid and clinical fractures and mortality after hip fracture.
Zoledronic acid significantly reduced new clinical fractures (by about a third) and was associated with a significant reduction in all-cause mortality.
Randomised trialManagementRheumatology & metabolic bone
HORIZON-PFTThe New England journal of medicine 2007
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Zoledronic acid markedly and significantly reduced vertebral fractures (around 70%) and significantly reduced hip fractures (around 40%) versus placebo.
Randomised trialManagementRheumatology & metabolic bone
FIT (alendronate)Lancet (London, England) 1996
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Alendronate roughly halved new radiographic vertebral fractures and also significantly reduced hip and wrist fractures compared with placebo.
Randomised trialManagementRheumatology & metabolic bone